import type { CompetitorRecord } from './competitor-database';

export const SPECIALTY_COMPETITORS_2: CompetitorRecord[] = [
  // ── Psoriasis / Psoriatic Arthritis ───────────────────────────────────────
  {
    asset_name: 'Skyrizi',
    generic_name: 'risankizumab',
    company: 'AbbVie',
    indication: 'Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis in adults',
    mechanism: 'IL-23 inhibitor (anti-p19)',
    mechanism_category: 'interleukin_inhibitor',
    molecular_target: 'IL-23 p19',
    phase: 'Approved',
    primary_endpoint: 'PASI 90 and sPGA 0/1',
    key_data: 'IMMhance: PASI 90 in 73% vs 2% placebo at week 16; superior to adalimumab',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Best-in-class PASI 90/100 rates', 'Q12W dosing after induction', 'Clean safety profile'],
    weaknesses: ['Crowded IL-23 class', 'Premium pricing vs biosimilar adalimumab'],
    source: 'FDA label; IMMhance/IMMvent trials; AbbVie 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Tremfya',
    generic_name: 'guselkumab',
    company: 'Johnson & Johnson',
    indication: 'Psoriasis',
    indication_specifics: 'Moderate-to-severe plaque psoriasis and active psoriatic arthritis',
    mechanism: 'IL-23 inhibitor (anti-p19)',
    mechanism_category: 'interleukin_inhibitor',
    molecular_target: 'IL-23 p19',
    phase: 'Approved',
    primary_endpoint: 'PASI 90 and IGA 0/1',
    key_data: 'VOYAGE 1/2: PASI 90 in 73% vs 3% placebo at week 16; durable through 5 years',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Long-term durability data', 'Q8W dosing', 'PsA + IBD data'],
    weaknesses: ['Slightly lower efficacy vs risankizumab in indirect comparisons'],
    source: 'FDA label; VOYAGE trials; J&J 2024 annual report',
    last_updated: '2025-01-15',
  },

  // ── Inflammatory Bowel Disease (Crohn's / UC) ────────────────────────────
  {
    asset_name: 'Stelara',
    generic_name: 'ustekinumab',
    company: 'Johnson & Johnson',
    indication: "Crohn's Disease",
    indication_specifics: "Moderate-to-severe Crohn's disease in adults with inadequate response to prior therapy",
    mechanism: 'IL-12/23 inhibitor',
    mechanism_category: 'interleukin_inhibitor',
    molecular_target: 'IL-12/23 p40',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission (CDAI < 150)',
    key_data: 'UNITI 1/2: Clinical remission 34-56% at week 8 (IV induction); maintained through 3 years',
    line_of_therapy: '2L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Dual IL-12/23 blockade', 'Strong safety profile', 'Long track record'],
    weaknesses: ['Biosimilar competition imminent (2025)', 'IV induction required'],
    source: 'FDA label; UNITI trials; J&J 2024 annual report',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Entyvio',
    generic_name: 'vedolizumab',
    company: 'Takeda',
    indication: 'Ulcerative Colitis',
    indication_specifics: 'Moderate-to-severe UC in adults with inadequate response to conventional therapy',
    mechanism: 'Anti-integrin (α4β7)',
    mechanism_category: 'integrin_inhibitor',
    molecular_target: 'α4β7 integrin',
    phase: 'Approved',
    primary_endpoint: 'Clinical remission at week 52',
    key_data: 'GEMINI 1: Clinical remission 41.8% vs 15.9% placebo at week 52',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Gut-selective mechanism (lower systemic immunosuppression)', 'SC formulation available', 'Strong UC data'],
    weaknesses: ['Slow onset of action', 'Less effective in Crohn\'s vs UC'],
    source: 'FDA label; GEMINI trials; Takeda 2024 annual report',
    last_updated: '2025-01-15',
  },

  // ── Migraine ──────────────────────────────────────────────────────────────
  {
    asset_name: 'Aimovig',
    generic_name: 'erenumab',
    company: 'Amgen / Novartis',
    indication: 'Migraine',
    indication_specifics: 'Preventive treatment of migraine in adults with ≥4 migraine days/month',
    mechanism: 'CGRP receptor antagonist',
    mechanism_category: 'cgrp_inhibitor',
    molecular_target: 'CGRP receptor',
    phase: 'Approved',
    primary_endpoint: 'Change in monthly migraine days',
    key_data: 'STRIVE: Reduction of 3.2-3.7 monthly migraine days vs 1.8 placebo at month 4-6',
    line_of_therapy: '1L',
    first_in_class: true,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['First-in-class CGRP mAb', 'Monthly SC injection', 'Well tolerated'],
    weaknesses: ['Constipation AE', 'Competing CGRP mAbs with similar efficacy'],
    source: 'FDA label; STRIVE trial; Amgen 10-K 2024',
    last_updated: '2025-01-15',
  },
  {
    asset_name: 'Ajovy',
    generic_name: 'fremanezumab',
    company: 'Teva',
    indication: 'Migraine',
    indication_specifics: 'Preventive treatment of migraine in adults',
    mechanism: 'Anti-CGRP antibody',
    mechanism_category: 'cgrp_inhibitor',
    molecular_target: 'CGRP ligand',
    phase: 'Approved',
    primary_endpoint: 'Change in monthly migraine days',
    key_data: 'HALO: Reduction of 4.3-4.6 monthly migraine days vs 2.5 placebo',
    line_of_therapy: '1L',
    first_in_class: false,
    orphan_drug: false,
    has_biomarker_selection: false,
    strengths: ['Quarterly dosing option', 'Targets CGRP ligand directly'],
    weaknesses: ['Crowded CGRP class', 'Lower brand recognition vs Aimovig'],
    source: 'FDA label; HALO trials; Teva 2024 annual report',
    last_updated: '2025-01-15',
  },
];
